While JenaValve is known for its Trilogy Heart Valve System, a device designed specifically to treat aortic regurgitation, Endotronix specializes in developing heart failure technologies. The news comes after Edwards sold its critical care business for $4.2 billion in June, saying it would double down on its structural heart portfolio. 

Businesses in the cardiovascular health space have been busy in recent weeks, announcing one big financing round after another. 

New one-year data suggests transseptal MViV with a Sapien 3 heart valve is a "favorable and safe procedure." Researchers plan to follow patients for a total of 10 years.

Researchers tracked SWEDEHEART data from more than 8,000 TAVR patients treated from 2008 to 2022. Overall, they said, PPM after TAVR was rare, and its impact on outcomes was "negligible."

Physicians and researchers complete thousands of clinical trials each year, but some findings prove far more significant than others. For cardiologist Dharmesh Patel, MD, the results of the SMART trial have changed the way he’s managing and recommending treatment for women with symptomatic severe aortic stenosis.

Some of the most talked about data at ACC.24 were the results of a late-breaking clinical trial comparing different transcatheter aortic valve replacement (TAVR) valves in patients with a small aortic annulus. 

The young patient was discharged 10 days later, and no postoperative complications have been reported.

Trainees interested in interventional cardiology will now be able to use the Match program to find the right program for their needs. The move is associated with multiple benefits as well as some key challenges.